

Yatin Suneja to join Guggenheim Securities as Biotech Analyst

27 August 2018 | News

Guggenheim Securities has hired four other senior analysts this year to expand the equity research therapeutics franchise: Seamus Fernandez, Whitney Ijem, Michael Schmidt, and Etzer Darout, in addition to Adnan Butt hired in 2017.



Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners has announced that Yatin Suneja will join the firm in November as a Managing Director, continuing the firm's planned expansion of the Healthcare Research team. Mr. Suneja will focus on the coverage of Biotechnology companies in close collaboration with our growing therapeutics team.

Mr. Suneja will bring over a decade of experience in Healthcare Equity Research. He will join Guggenheim from SunTrust Robinson Humphrey where he was a Managing Director and Biotechnology analyst covering therapeutic areas in the healthcare space. Prior to SunTrust, he was a Vice President on the Cowen and Company biotechnology research team. He began his career at Bank of America in Corporate Banking.

"Yatin is a great addition to our growing healthcare equity research team," said Stefano Natella, Co-Head of Equities. "He will bring valued insight through his deep-dive approach and further expand the breadth of Guggenheim's therapeutics research platform. We look forward to his success at Guggenheim."

Guggenheim Securities has hired four other senior analysts this year to expand the equity research therapeutics franchise: Seamus Fernandez, Whitney Ijem, Michael Schmidt, and Etzer Darout, in addition to Adnan Butt hired in 2017.

Mr. Suneja received his M.B.A. from The Martin J. Whitman School of Management at Syracuse University and his B.Com. in Economics and Accounting from PGDAV College at the University of Delhi in New Delhi, India. He will be based in Guggenheim's New York office.